Lobo Genetics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

lobogene.com

Founded Year

2018

Stage

Acquired | Acquired

About Lobo Genetics

Lobo Genetics enables safer cannabis use through DNA testing. Consumers and patients can gain insights into personal responses to cannabis-based on their genetic profiles. Lobo's portable device platform provides results in under an hour and can be deployed in medical clinics, dispensaries, pharmacies, or retail outlets. On June 16th, 2021, Lobo Genetics was acquired by Entheon Biomedical. The terms of the transaction were not disclosed.

Lobo Genetics Headquarter Location

40 University Avenue, Suite 1003

Toronto, Ontario, M5J 1T1,

Canada

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Lobo Genetics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Lobo Genetics in 1 CB Insights research brief, most recently on Jun 14, 2019.

Expert Collections containing Lobo Genetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lobo Genetics is included in 1 Expert Collection, including Cannabis.

C

Cannabis

3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

Latest Lobo Genetics News

Spartan creditors strike deal to keep biotech firm operating, if the court agrees

Sep 3, 2021

Article content The upshot is a deal that, if approved by a bankruptcy judge on Friday, would see Spartan survive as a standalone firm, free to market its portable COVID-19 testing technology known as the Cube. We apologize, but this video has failed to load. Try refreshing your browser, or Spartan creditors strike deal to keep biotech firm operating, if the court agrees Back to video Whether the federal government will continue to stand by its $149-million order for Spartan’s test kits is unknown. Spartan burst out of the gate 18 months ago, having adapted its Cube — which uses DNA technology to test for pathogens such as legionella — for the war against the novel coronavirus. An early version received Health Canada approval for sale. But this was rescinded when it turned out Spartan’s proprietary swabs were substandard. A re-engineering effort followed, along with a clinical trial. Health Canada gave its seal of approval last January. Advertisement Article content A second, unspecified technical glitch forced to Spartan to recall its product and file for creditor protection in April. Health Canada’s approval remains and there are hints the technical issue, seemingly minor, has finally been fixed. Casa-Dea, a family trust that extended Spartan a $7-million bridge loan last autumn, has been the main driver in trying to keep Spartan afloat. Darrell Edgett is the director of both Casa-Dea and 2856031 Ontario Inc., the numbered company created to hold Spartan’s assets and to employ remaining workers. Steve Edgett, his brother, is a senior Spartan executive. Under the terms of a deal reached late in August, Casa-Dea will acquire BDC’s $9-million claim. In turn, the numbered company will assume Casa-Dea’s $7-million loan as well as the BDC loan on which the $9-million claim is based. The legal fight had been waged over which of the two claims should assume priority. This solution gets around that problem. Advertisement Article content As part of the consideration for the deal, BDC will receive all shares currently held by Spartan in Lobo Genetics, a Toronto-based startup that uses the Cube to do genetic testing of cannabis users to assess their responses to the drug. It was started by Spartan co-founder John Lem (brother of Paul Lem, also a Spartan co-founder) and was acquired five weeks ago by Entheon, a Vancouver R&D firm. Entheon paid for Lobo Genetics by agreeing to issue five million shares, valued at 33 cents each, at the time of the deal. Court documents filed recently by Ernst & Young, the bankruptcy monitor, noted that Spartan’s stake in Lobo Genetics was just shy of 26 per cent. That would give the piece potentially being acquired by BDC a current value of less than half a million dollars. Advertisement Article content BDC Capital, which is in the business of investing in startups, clearly sees something it likes in Entheon, which is trying to commercialize therapeutic products for treating people with substance use disorders. The court filing Thursday by the monitor did not spell out what other considerations BDC would receive, or their value, for agreeing to dispose of its claim against Spartan. Assuming the bankruptcy judge approves the new arrangement Friday, Casa-Dea for its part will be able to get on with the job of trying to generate profits from a COVID-19 testing technology that still has a lot to prove. Share this article in your social network Share this Story: Spartan creditors strike deal to keep biotech firm operating, if the court agrees

Lobo Genetics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lobo Genetics Rank

  • When was Lobo Genetics founded?

    Lobo Genetics was founded in 2018.

  • Where is Lobo Genetics's headquarters?

    Lobo Genetics's headquarters is located at 40 University Avenue, Suite 1003, Toronto.

  • What is Lobo Genetics's latest funding round?

    Lobo Genetics's latest funding round is Acquired.

  • Who are the investors of Lobo Genetics?

    Investors of Lobo Genetics include Entheon Biomedical.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.